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label the therapy as primitive would not
do justice to the resounding success in
the number of lives saved and the dedi-
cated professionals who pioneered
cures for these children.The fact is that if
the 75% cure rate seen today was estab-
lished with only modest insight into the
underlying biology of ALL, then we
should expect nothing short of 100%
cure as well as successful preventive
strategies in the decades to come.
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Myeloproliferative disorders (MPDs) are
clonal malignancies characterized 
by overproduction of one or more
hematopoietic lineages with relatively
normal differentiation (Van Etten and
Shannon, 2004). The World Health
Organization (WHO) classifies chronic
myeloid leukemia (CML), polycythemia
vera (PV), essential thrombocythemia
(ET), chronic idiopathic myelofibrosis
(CIMF), and the related disorders chron-
ic eosinophilic leukemia (CEL) and idio-
pathic hypereosinophilic syndrome
(HES) as distinct MPDs. Atypical CML,
chronic myelomonocytic leukemia
(CMML), and juvenile myelomonocytic
leukemia (JMML) comprise a related
group of “overlap” disorders in which
myeloproliferation is prominent, but the
bone marrow also shows aberrant matu-
ration (myelodysplasia). Laboratory and
clinical observations such as de novo
chromosomal translocations (e.g.,
t[9;22] in CML and t[5;12] in some cases
of CMML), an increased risk of JMML in
children with neurofibromatosis and
Noonan syndrome, and the unexpected
responses of some patients with HES to
imatinab mesylate provided clues that
facilitated identifying molecular lesions
that play a central role in the pathogene-
sis of MPDs and “overlap” diseases
(Figure 1). Aberrant activation of kinase
signaling cascades and hyperactive Ras
have emerged as common biochemical
themes in these disorders, and studies in
animal models strongly imply that many
of the mutations found in human patients
can initiate MPD-like diseases in vivo
(Van Etten and Shannon, 2004).
A paper by Levine et al. (2005) in this
issue of Cancer Cell, and data published
in the Lancet and Nature (Baxter et al.,
2005; James et al., 2005), report JAK2
point mutations in most patients with PV
and in a substantial proportion of ET and
CIMF. These results are satisfying, as
they follow logically from the known role
of the JAK2 kinase in hematopoietic pro-
liferation and are consistent with previous
studies of PV patient samples. The four
mammalian Janus (JAK) kinases are
recruited by ligand binding to cytokine
receptors, where they are activated by
trans-phosphorylation and, in turn, phos-
phorylate critical tyrosine residues on the
receptor that can then serve as docking
sites for members of the STAT (signal
transducer and activation of transcription)
family and for other signaling molecules
(O’Shea et al., 2002). Specific cytokine
receptors recruit and activate distinct
pairs of JAK and STAT proteins. JAK2 is
the primary tyrosine kinase activated by
erythropoietin (EPO), and is essential for
definitive erythropoiesis (Parganas et al.,
1998). Many of the effects of JAK2 are
mediated through the recruitment of
STAT5 to phospotyrosyl residues on the
EPO, interleukin 3 (IL-3), and granulo-
cyte-macrophage colony stimulating fac-
tor (GM-CSF) receptors. Interestingly,
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Mutations that deregulate proliferation and survival pathways have emerged as a common molecular theme in the patho-
genesis of myeloproliferative disorders (MPDs).Three studies now report an amino acid substitution in the JAK2 kinase in
most patients with polycythemia vera as well as in some cases of essential thrombocythemia and chronic idiopathic
myelofibrosis. Functional analysis demonstrates that this mutation confers erythropoietin-independent growth in vitro,
deregulates signaling pathways downstream of JAK2, and causes polycythemia in mice.These results open new avenues
for diagnosing and classifying patients with these disorders, and identify a new molecular target for drug discovery.
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compound Stat5a/b mutant mice demon-
strate fetal anemia and impaired ery-
throid progenitor colony growth, which is
associated with failure to induce the anti-
apoptotic family member Bcl-XL in
response to EPO (Socolovsky et al.,
1999). By contrast, bone marrow cells
from PV patients form EPO-independent
endogenous erythroid colonies (EEC) in
methylceullose, and Bcl-XL protein levels
are increased in PV erythroblasts (Silva
et al., 1998). While the molecular basis of
EEC was unknown until now, it was
thought likely that the relevant
mutation(s) were downstream of the EPO
receptor, which is not mutated in PV and
has normal expression and affinity for
EPO. The new reports confirm this spec-
ulation, and identify a single amino acid
substitution in the JH2 pseudokinase
domain of JAK2—V617F—as a prevalent
molecular lesion in PV, ET, and CIMF.
JAK2 mutations were detected in PV,
ET, and CIMF specimens through two
general experimental strategies. James
and coworkers (James et al., 2005) iden-
tified JAK2 as a candidate PV gene on
the basis of experiments in which they
found that a JAK2 kinase inhibitor and a
short interfering RNA molecule impaired
EEC formation from PV bone marrows.
The other two groups uncovered JAK2
mutations by pursuing systematic
“kinome” sequencing efforts of MPD
specimens (Baxter et al., 2005; Levine et
al., 2005). Analysis of over 300 primary
PV specimens revealed the V617F sub-
stitution in 73%–97% of cases (Baxter et
al., 2005; James et al., 2005; Levine et
al., 2005). The true incidence may
approach the 97% frequency reported by
Baxter et al. (2005), as these investiga-
tors used a sensitive allele-specific PCR-
based strategy to detect alleles that were
present in a minority of nucleated bone
marrow cells. The mutation was present
in differentiated myeloid and erythroid
cells and in progenitor colonies grown
from PV patient samples, but was not
identified in T lymphocytes (Baxter et al.,
2005; James et al., 2005; Levine et al.,
2005). Interestingly, the mutation was
also identified in buccal swab DNA from
a small proportion of patients, which
infers that the inciting genetic lesion is
occasionally present in the germline
(Levine et al., 2005).The V617F substitu-
tion was also detected in a significant
percentage of ET and CIMF specimens,
thereby implicating the same molecular
lesion in all three types of MPD. Another
striking result was the finding of biallelic
mutations in ?30% of the PV specimens.
Analysis of polymorphisms showed this
to be due to a mitotic recombination
event that ablated the remaining normal
allele. These new data, which are
remarkably consistent with a previous
study that demonstrated loss of constitu-
tional heterozygosity in PV specimens
within a segment of chromosome band
9p that contains the JAK2 locus
(Kralovics et al., 2002), emphasize that
this genetic mechanism is not invariably
associated with tumor suppressor gene
inactivation, but can also be a marker of
proto-oncogene activation.
Levine et al. (2005) observed EPO-
independent survival and hypersensitivity
in the Ba/F3-EPOR cells engineered to
express V617F JAK2. These investiga-
tors also coexpressed wild-type JAK2
with the mutant protein in 293T cells, but
did not find that this interferes with
autophosphorylation of V617F JAK2.
They also identified the PV-associated
mutation in HEL cells, and showed that
this was associated with elevated levels
of STAT5 and ERK phosphorylation, and
with sensitivity to a small molecule
inhibitor. James et al. (2005) performed
an extensive functional analysis of V617F
JAK2 in cell lines and in murine bone
marrow. Importantly, they demonstrated
that V617F JAK2, but not the wild-type
protein, could activate STAT5-dependent
transcription. Other studies showed that
V617F JAK2 induces EPO hypersensitiv-
ity and aberrant activation of STAT5, Akt,
and ERK in cell lines. Interestingly, coex-
pressing wild-type JAK2 with the mutant
protein restored EPO dependence in
Ba/F3 cells. This finding, which is consis-
tent with loss of the wild-type JAK2 allele
in ?30% of human PV specimens, infers a
dominant interfering activity of the normal
protein and a selective growth advantage
for cells that have deleted it. Based on the
data of Levine et al. in 293T cells (Levine
et al., 2005), it is possible that wild-type
JAK2 does not directly downregulate the
mutant protein, but instead competes for
binding sites on cytokine receptors. Since
JAK2 molecules that are recruited to acti-
vated homo- or heterodimeric receptors
trans-phosphorylate each other, it is not
difficult to envision how retaining normal
protein expression could impede the abili-
ty of V617F JAK2 to constitutively activate
downstream effectors. Further work will be
required to resolve this question. In a final
series of experiments that directly estab-
lish the relevance of the mutation to the PV
phenotype, James and coworkers (James
et al., 2005) found that recipient mice that
were transplanted with cells engineered to
express V617F JAK2 developed erythro-
cytosis.
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Figure 1. Molecular lesions identified in MPD
Overview of mutant proteins detected in
specific subtypes of MPD and overlap dis-
eases with putative connections to cellular
signaling networks. Proteins that are altered
by dominantly acting mutations are shown in
green, while the known instance of tumor
suppressor gene inactivation (loss of NF1) is
shown in red. JAK2 phosphorylates tyrosine
residues on activated growth factor recep-
tors that serve as docking sites for STAT5 and
other effectors. See text and Van Etten and
Shannon (2004) for further discussion and
additional information.
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Together, these three reports firmly
establish somatic JAK2 mutations as a
prevalent genetic lesion in PV that plays
an integral role in the disease pheno-
type. Remarkably, every patient sample
contained the same amino acid substitu-
tion. Based on the predicted JAK2 struc-
ture, the V-to-P substitution at codon 617
disrupts an autoinhibitory interaction
between the JH2 and kinase domains of
the protein. This pathogenic mechanism
is reminiscent of somatic PTPN11 muta-
tions in JMML, which encode amino acid
substitutions that constitutively activate
the SHP-2 phosphatase. Other parallels
with PV include the consistent GM-CSF
hypersensitivity seen in JMML, the find-
ing of germline mutations in some
patients, the ability of wild-type and
mutant SHP-2 to activate multiple down-
stream effector pathways by binding to
phosphotyrosyl residues on growth fac-
tor receptors, the limited spectrum of
PTPN11 mutations found in leukemias,
and occasional JMML samples that
demonstrate both a somatic PTPN11
mutations and loss of the normal allele
(Loh et al., 2004; Tartaglia et al., 2003).
These three studies also raise
provocative new questions regarding the
role of JAK2 mutations in MPD. Perhaps
the most interesting of these is how the
same mutation is associated with three
diseases that have distinct clinical fea-
tures. EECs are observed in approxi-
mately half of ETs, and it seems likely
that these cases will be associated with
the V617F JAK2 substitution, whereas
the myelofibrosis patients could be PV
patients presenting in the so-called
“spent” phase of the disease. While it is
possible that the diverse clinical spec-
trum reflects transformation of distinct
progenitors, recent data in mouse mod-
els supports the idea that proliferative
mutations such as JunB deficiency and
oncogenic Kras expression do not
enhance self-renewal and must occur in
the hematopoietic stem cell (HSC) com-
partment to induce overt disease (Braun
et al., 2004; Passegue et al., 2004).
Although T lymphocytes are not involved
in the clonal outgrowth of V617F JAK2-
expressing cells in PV, they are also pre-
dominantly negative for the Ph
chromosome in CML, and hence this
does not preclude the possibility that the
initiating mutation occurs in HSCs with
subsequent selection against their prog-
eny during lymphocyte differentiation.
Generating conditional knockin strains of
mice harboring the V617F JAK2 muta-
tion may help to resolve this issue.
Alternatively, somatic JAK2 mutations
may initiate PV (and perhaps ET), but
represent cooperating events in CIMF. A
similar model has been proposed to
explain the existence of KRAS2 and
NRAS mutations in both MPD and acute
myeloid leukemia (Braun et al., 2004).
The underlying cause of the MPD in
those patients lacking the JAK2 V617F
mutation awaits further investigation, but
the work of Levine et al. (2005) suggest
that the offending lesion is not in another
tyrosine kinase. Finally, these exciting
studies open new avenues for diagnos-
ing and classifying patients with MPD,
and for developing targeted therapeutics
to inhibit the mutant V617F JAK2 kinase.
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